These results suggest that increased expression of both UBE2NL and HIST2H3PS2 is associated with disease progression and may serve as potential molecular markers to differentiate benign, early-stage, and advanced-stage ovarian tumors. Here, UBE2NL is linked to ovarian neoplasm.